Haven't used Innovative Biologics yet?
Ask AI

What reviewers say about Innovative Biologics

Generated with AI from 11 reviews on Trustburn · updated 30 days ago

Customers generally describe Innovative Biologics positively, frequently highlighting high product quality, effectiveness, strong customer service, and impressive research and innovation, with consistent praise across both the cross-section and the lowest-rated excerpts.
What does Innovative Biologics do?

Innovative Biologics is an anti-infective small molecule drug discovery and development company that targets microbes producing pore-forming toxins, such as MRSA and Hepatitis C, using its CycloPlex™ platform built around a β-cyclodextrin scaffold. The company identifies compounds that block the target pore by matching its symmetry.

What are the most common complaints about Innovative Biologics?

The information available does not indicate any recurring complaints about Innovative Biologics, as the critical reviewers on file actually described positive impressions of the products, research, and innovation rather than specific issues.

AI-generated from reviews on this page. Verify anything important with the company directly.

Questions & Answers

No questions yet — be the first to ask.

News & Press

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying widget on your website — its a simple way to convert your visitors into customers.

Embed code

<script src="https://trustburn.com/widgets/index.js"></script>
<div class="trustburn-widget" data-trustburn-protocol="https:" data-trustburn-domain="trustburn.com" data-trustburn-widget="score" data-company-path="innovbio-com" data-lang="en"></div>
More widgets

About Innovative Biologics

Innovative Biologics (IBI) is an anti-infective small molecule drug
discovery and development company targeting microbes producing pore-forming toxins, such as MRSA and Hepatitis C. Many pathogens utilize the formation of pores in the membranes of target cells in the process of infection. IBI has developed the CycloPlex™ platform to identify compounds which inhibit their action, based on blocking the target pore with molecules having the same symmetry as the pore itself, using ß-cyclodextrin as a scaffold.